title: Validity of current recommendation for peri-operative interruption of warfarin in Asians.
abstract: Temporary interruption of anticoagulation therapy is usually recommended for anticoagulated patients undergoing invasive procedures to minimize their bleeding risks. We validated the current consensus recommendation on warfarin interruption which were based on Western population studies to determine if they could safely be applied to Asians. The international normalized ratios (INR) in twenty warfarinised patients with a stable INR of 2-3 were prospectively measured at days 0, 3 and 5 after stopping warfarin for procedures or at completion of treatment. The median INR at days 0, 3 and 5 were 2.30 (95% CI 2.16-2.43), 1.32 (95% CI 1.22-1.57) and 1.06 (95% CI 1.05-1.13) respectively (P < 0.001 for trend). All patients were below therapeutic INRs by day 3 with 14 patients (70%, 95% CI 49.92-90.08) achieving INR readings below 1.5. By day 5, all INRs were below 1.5 and only 2 patients (10%, 95% CI -3.15 to 23.15) had INRs above 1.2. There were no significant peri-procedure bleeding or thrombotic events in the 1 month following interruption of warfarin. Our results suggest that the current international recommendation of stopping warfarin for 5 days prior to procedure can safely be applied to Asians without compromising risk of bleeding or thrombosis.
authors.affiliation: Department of Pharmacy, Singapore General Hospital, Singapore.
authors.forename: Sei Keng
authors.initials: SK
authors.lastname: Koh
authors.forename: Heng Joo
authors.initials: HJ
authors.lastname: Ng
authors.forename: Ming Chai
authors.initials: MC
authors.lastname: Kong
authors.forename: Yiong Huak
authors.initials: YH
authors.lastname: Chan
authors.forename: Lai Heng
authors.initials: LH
authors.lastname: Lee
mesh_terms: D000368:Aged; D044466:Asian People; D016063:Blood Loss, Surgical / Q000517:prevention & control; D005260:Female; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D019990:Perioperative Care / Q000379:methods*; D017410:Practice Guidelines as Topic / Q000592:standards*; D013927:Thrombosis / Q000517:prevention & control; D013997:Time Factors; D014859:Warfarin / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D014859:Warfarin
references.citation: Chest. 2008 Jun;133(6 Suppl):299S-339S
references.pmid: 18574269
references.citation: Genetics. 1992 Jan;130(1):139-52
references.pmid: 1346259
references.citation: Hum Genet. 2007 Mar;121(1):23-34
references.pmid: 17048007
references.citation: Trends Pharmacol Sci. 2009 Jul;30(7):375-86
references.pmid: 19540002
references.citation: Thromb J. 2008 Oct 16;6:15
references.pmid: 18925967
references.citation: Clin Pharmacokinet. 1996 Apr;30(4):300-13
references.pmid: 8983860
references.citation: Ann Intern Med. 2001 Sep 18;135(6):393-400
references.pmid: 11560452
references.citation: Stroke. 2009 Jun;40(6):2276-93
references.pmid: 19423857
references.citation: Clin Pharmacol Ther. 2004 Sep;76(3):210-9
references.pmid: 15371982
references.citation: Ann Intern Med. 1995 Jan 1;122(1):40-2
references.pmid: 7985894
references.citation: Br J Haematol. 2004 Feb;124(3):348-54
references.pmid: 14717783
references.citation: Circulation. 2009 Jun 9;119(22):2920-7
references.pmid: 19470892